By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback